Patents by Inventor Bryon S. DROWN

Bryon S. DROWN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecules active against gram-negative bacteria
    Patent number: 11858946
    Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: January 2, 2024
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
  • SMALL MOLECULES ACTIVE AGAINST GRAM-NEGATIVE BACTERIA
    Publication number: 20220112203
    Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.
    Type: Application
    Filed: May 3, 2021
    Publication date: April 14, 2022
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
  • FLUORESCENT SUBSTRATES FOR POLY(ADP-RIBOSYL) HYDROLASES
    Publication number: 20220050112
    Abstract: The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or liberate monomers from their protein targets. Disclosed herein is a substrate for monitoring PARG activity, TFMU-ADPr, which directly reports on total PAR hydrolase activity via release of a fluorophore; this substrate has excellent reactivity, generality, stability, and usability. A second substrate, TFMU-IDPr, selectively reports on PARG activity only from the enzyme ARH3. Use of these probes in whole-cell lysate experiments has revealed a mechanism by which ARH3 is inhibited by cholera toxin. TFMU-ADPr and TFMU-IDPr are versatile tools for assessing small-molecule inhibitors in vitro and probing the regulation of ADP-ribosyl catabolic enzymes.
    Type: Application
    Filed: September 9, 2019
    Publication date: February 17, 2022
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Bryon S. DROWN